Hawk Ridge Capital Management LP Acquires New Stake in The Cooper Companies, Inc. $COO

Key Points

• Hawk Ridge Capital Management LP has acquired a new position in The Cooper Companies, Inc., purchasing 423,900 shares valued at approximately $35.76 million.
• Institutional investors and hedge funds collectively own 24.39% of The Cooper Companies' stock, indicating significant interest from the investment community.
• This acquisition follows a positive quarterly earnings report, with Cooper Companies beating analysts' estimates by posting $1.10 earnings per share compared to the expected $1.07.

Hawk Ridge Capital Management LP purchased a new position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 423,900 shares of the medical device company's stock, valued at approximately $35,756,000. Cooper Companies makes up approximately 1.7% of Hawk Ridge Capital Management LP's investment portfolio, making the stock its 23rd largest position. Hawk Ridge Capital Management LP owned approximately 0.21% of Cooper Companies as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT acquired a new stake in shares of Cooper Companies in the 1st quarter valued at about $33,000. City Holding Co. bought a new stake in Cooper Companies during the first quarter worth approximately $34,000. GKV Capital Management Co. Inc. acquired a new position in Cooper Companies in the 1st quarter worth approximately $40,000. Larson Financial Group LLC boosted its stake in Cooper Companies by 1,071.0% in the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company's stock worth $61,000 after purchasing an additional 664 shares during the period. Finally, HM Payson & Co. lifted its position in Cooper Companies by 147.4% in the 1st quarter. HM Payson & Co. now owns 893 shares of the medical device company's stock worth $75,000 after buying an additional 532 shares in the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Brian G. Andrews acquired 1,525 shares of the stock in a transaction on Tuesday, September 2nd. The stock was acquired at an average price of $65.68 per share, with a total value of $100,162.00. Following the completion of the transaction, the executive vice president owned 22,191 shares of the company's stock, valued at $1,457,504.88. This represents a 7.38% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Albert G. White III bought 10,000 shares of the firm's stock in a transaction on Friday, September 5th. The stock was acquired at an average cost of $68.39 per share, with a total value of $683,900.00. Following the transaction, the chief executive officer owned 226,151 shares in the company, valued at $15,466,466.89. The trade was a 4.63% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 15,975 shares of company stock worth $1,079,566. Insiders own 1.98% of the company's stock.

Wall Street Analyst Weigh In

COO has been the subject of a number of research reports. Wells Fargo & Company decreased their target price on shares of Cooper Companies from $93.00 to $72.00 and set an "overweight" rating for the company in a research note on Thursday, August 28th. Robert W. Baird dropped their target price on shares of Cooper Companies from $97.00 to $85.00 and set an "outperform" rating on the stock in a report on Thursday, August 28th. UBS Group upgraded shares of Cooper Companies to a "buy" rating in a report on Tuesday, June 17th. BNP Paribas Exane upgraded shares of Cooper Companies from a "neutral" rating to an "outperform" rating and set a $92.00 target price on the stock in a research report on Tuesday, July 22nd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $94.00 target price on shares of Cooper Companies in a research report on Thursday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $86.64.

Cooper Companies Trading Down 1.0%

Shares of NASDAQ COO traded down $0.67 during midday trading on Tuesday, reaching $68.12. The stock had a trading volume of 980,955 shares, compared to its average volume of 2,294,687. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12. The Cooper Companies, Inc. has a twelve month low of $61.78 and a twelve month high of $112.38. The company's 50 day moving average price is $71.94 and its 200 day moving average price is $76.43. The firm has a market cap of $13.54 billion, a price-to-earnings ratio of 33.47, a price-to-earnings-growth ratio of 1.72 and a beta of 0.97.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the business earned $0.96 earnings per share. The firm's revenue for the quarter was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.